Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth

Q4 loss per share narrowed year-over-year as revenue grew on stronger sales of retina systems and glaucoma probes. Margins remain pressured by higher costs, leaving profitability improvement incomplete and suggesting a cautious near-term outlook for earnings recovery.

Analysis

Q4 loss per share narrowed year-over-year as revenue grew on stronger sales of retina systems and glaucoma probes. Margins remain pressured by higher costs, leaving profitability improvement incomplete and suggesting a cautious near-term outlook for earnings recovery.